# Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

> **NCT01796197** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 23 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Paclitaxel
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Mastectomy
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT01796197
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2018-06
- **Final completion:** 2026-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01796197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01796197, "Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01796197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*